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Anti-GBM glomerulonephritis in mice lacking nitric oxide synthase
type 2. Rapid Communication. Nitric oxide is synthesized in experimental
immune complex glomerulonephritis due to local induction of type 2 nitric
oxide synthase (NOS2). To determine the role of NOS2, the course of
accelerated anti-glomerular basement membrane glomerulonephritis (an-
ti-GBM) was examined in mice homozygous for disruption of the NOS2
gene compared with heterozygous littermates. Disease in the wild type
strain (129Sv) was characterized by heavy albuminuria, glomerular neu-
trophil and macrophage infiltration and glomerular thrombosis. NOS2,
interleukin 1B (IL-1b) and tumor necrosis factor a (TNFa) mRNA were
induced by 24 hours. The NOS2-deficient mutant mice and the heterozy-
gous mice displayed early (24 hr) and full autologous phase (day 6) injury
indistinguishable from the wild-type mice. The equivalent degree of
albuminuria and glomerular inflammation indicates that NOS2 does not
play an essential role in this form of glomerulonephritis in the mouse.
In experimental immune complex glomerulonephritis nitric
oxide (NO) is synthesized by nephritic glomeruli [1–4]. NO
synthesis results from the induction of the high output, calcium
independent isoform of nitric oxide synthase (iNOS or NOS2);
NOS2 mRNA can be demonstrated in glomeruli by ribonuclease
protection assay [5] and reverse transcriptase (RT)-polymerase
chain reaction (PCR) [6, 7] and NOS2 protein by immunohisto-
chemistry [8] in models of glomerulonephritis. The role of NOS2
in glomerulonephritis, however, remains controversial. NO has
the potential to increase glomerular injury by its direct cytotoxic
actions [9], but may also have protective actions by improving
glomerular hemodynamics [10], inhibiting thrombosis [11] and
adhesion molecule expression [12], and scavenging other free
radicals such as superoxide [13]. Experiments to define a role for
NOS2 have been hampered by the lack of completely selective
inhibitors of NOS2; the major NOS inhibitors also inhibit endo-
thelial NOS3 leading to hypertension, a factor known to exacer-
bate glomerulonephritis [14]. Some groups have therefore used
indirect methods to manipulate NOS2 activity, such as alteration
of substrate availability either by dietary supplementation with
L-arginine [15] or administration of arginase [16] to deplete
circulating arginine. Overall the results are inconclusive with some
experiments pointing to a toxic role for NO [17, 18] and others
suggesting that it is protective [16]. Therefore, in order to
determine the role of NOS2 in glomerulonephritis, we have now
examined the course of glomerulonephritis in mice that are
homozygous for a disruption of the NOS2 gene and compared
them with heterozygous littermates with functional NOS2.
METHODS
Mice
The derivation of mice with genetically disrupted NOS2 gene
has been previously described [19]. The chimeras were bred into
the inbred 129 strain (Harlan Olac, Bicester, UK). The mice were
kept in an isolator at the University of Glasgow and maintained as
homozygous or heterozygous littermates. DNA from each indi-
vidual mouse was examined by Southern blot analysis to confirm
the genotype for NOS2. Adult male mice (8 to 10 weeks of age
were transferred to Imperial College School of Medicine where
experiments were performed. Mice were negative for common
murine viral pathogens by sera analyses.
Preliminary experiments establishing the model of accelerated
anti-glomerular basement membrane (anti-GBM) glomerulone-
phritis in the 129Sv mouse and techniques for mouse glomerular
isolation were performed on adult male 129Sv mice from Harlan
Olac.
Induction and monitoring of glomerulonephritis
Mice were immunised with a single intraperitoneal dose of 0.2
mg rabbit IgG (Sigma, Poole, UK) in Freund’s complete adjuvant
(Sigma). Rabbit anti-mouse glomerular basement membrane an-
tibody (globulin concentration 15 mg/ml) [20] was given intrave-
nously seven days later. In preliminary experiments doses of
between 0.2 to 3 mg anti-GBM globulin per mouse were used to
establish a reproducible model of accelerated anti-GBM nephritis
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with glomerular NOS2 induction in the 129Sv mouse strain. Mice
were killed at one, three or six days.
In the two principal experiments described here, NOS2 defi-
cient and NOS2 heterozygous mice received either 0.6 mg anti-
GBM globulin and were killed at 24 hours, or 0.3 mg anti-GBM
globulin and were killed 24 hours or six days later. Kidneys were
removed for glomerular isolation, histology and immunohisto-
chemistry. Mice were housed in metabolic cages for urine collec-
tion.
Urinalysis
Urine was collected for 24 hour periods. Albuminuria was
measured by rocket immunoelectrophoresis using sheep anti-rat
albumin antibody [21] (Biogenesis Ltd., Poole, UK). Creatinine
was measured by the Jaffe reaction on an automatic analyzer.
Glomerular isolation
Magnetizable iron oxide was prepared as described [22]. A
diethyl pyrocarbonate (DEPC) treated sterile suspension of iron
oxide (1.25% wt/vol) in 0.9% saline solution was prepared and
passed four times through a 25 gauge needle. Mice were killed by
cervical dislocation and perfused through the left ventricle with 10
mls of iron oxide suspension. The kidneys were removed and
sieved through a 75 mm sieve. The resulting suspension of
glomeruli and tubules was washed three times with phosphate
buffered saline (PBS) with centrifugation at 300 g and resus-
pended in 1 ml of DEPC treated PBS. Glomeruli were concen-
trated by washing three times with DEPC PBS under a magnetic
field from a Dyna magnetic particle concentrator (MPC-E, Dynal,
UK). Glomerular preparations obtained using this method rou-
tinely had a purity of . 95%.
Reverse transcription polymerase chain reaction
Glomerular pellets from individual animals were snap frozen
and stored at 270°C before mRNA extraction which was carried
out with RNAzol B (Biogenesis, Poole, UK) following the man-
ufacturer’s instructions. The entire RNA sample from each ani-
mal was reverse transcribed with Moloney murine leukemia virus
enzyme (Gibco BRL, Paisley, UK) according to the manufactur-
er’s instructions. The resulting cDNA was amplified by PCR using
primers against NOS2 (735 bp product) and b-actin (202 bp) as
reported previously [6] and for interleukin-1B (IL-1b; sense,
59-GCA-ACT-GTC-CCT-GAA-CTC-A-39; antisense, 59-GCC-
CAA-GGC-CAC-AGG-GAT-T-39, 528 bp) and TNFa (sense,
59-GGA-TCA-TCT-TCT-CAA-AAC-TCG-59; antisense, 59-
TCA-CAG-AGC-AAT-GAC-TCC-AAA-39, 468 bp). PCR was
carried out for 35 (NOS2, b-actin) or 40 cycles with the following
sequential steps: 72°C for one minute, 60°C for 30 seconds and
94°C for 30 seconds. The identity of the NOS2 PCR product was
confirmed by restriction enzyme digestion with AvaI and with
StuI, which produced products of the predicted sizes. PCR
products were analyzed on 1% agarose gel and visualized with
ethidium bromide staining and ultraviolet light transillumination.
Histology
Kidneys were fixed in 10% buffered formal saline, paraffin
embedded and stained with hematoxylin and eosin (H&E) and
periodic acid-Schiff (PAS). For neutrophil counts sections were
stained with chloroacetate esterase and a minimum of twenty
glomeruli per section counted; results are expressed as neutro-
phils per glomerular cross section.
Glomeruli thrombi were scored as 0 to 4 for each glomerulus
depending on the number of quadrants involved and a mean
obtained for at least twenty glomeruli as previously described [16]
Immunohistochemistry
Kidney was fixed in paraformaldehyde, lysine, periodate fixative
[23] for four hours at 4°C, washed in 7% sucrose overnight and
frozen in isopentane cooled in liquid nitrogen. Tissue sections
were cut and stained with monoclonal anti-mouse CD68 (FA/11;
a kind gift from Dr. Andrew McKnight, Oxford, United King-
dom), to detect macrophages. The primary antibody was detected
using biotinylated rabbit anti-rat antibody and streptavidin biotin
peroxidase.
Statistics
Results are expressed as mean 6 standard error and compari-
sons between groups are by Student’s t-test.
RESULTS
Induction of glomerulonephritis
Immunization followed by anti-GBM antibody in the 129Sv wild
type strain resulted in an accelerated nephrotoxic nephritis with
persistent albuminuria up to 55 mg per 24 hours (normal 129Sv
mice, albuminuria , 0.05 mg/24 hr). Histologically, at 24 hours
there was neutrophil polymorphonuclear leukocyte infiltration
and segmental glomerular thrombosis (Fig. 1). NOS2 mRNA was
detected in glomeruli at 24 hours and nine days; NOS2 message
was not present in normal glomeruli. From 6 to 9 days there was
glomerular thrombosis and mild glomerular hypercellularity to-
gether with small cellular crescents in 10% of glomeruli (Fig. 2).
There was focal tubular dilatation with eosinophilic casts and a
focal, mild, interstitial mononuclear cell infiltrate. These changes
increased in severity with increasing doses of anti-GBM antibody,
and with 3 mg of antibody there was total glomerular thrombosis
with non-perfusable kidneys.
The presence of neutrophils and a high level of albuminuria at
Fig. 1. Glomerulus 24 hours after induction of glomerulonephritis.
There is prominent thrombosis (arrows). An infiltrating neutrophil is
present (arrowhead) (periodic acid-Schiff 3500).
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24 hours suggested an early neutrophil-dependent phase of dis-
ease, preceding autologous disease. In experiments to assess the
effect of NOS2 deficiency in these two phases, we therefore
examined early (24 hr) injury, using a dose of 0.6 mg anti-GBM
antibody, and autologous phase injury at six days using a lower
dose of 0.3 mg. The lower dose was chosen to ensure significant
survival at six days.
Experiment 1. Early injury (24 hours)
Disease was induced in 10 NOS2 mutant and 10 NOS2 het-
erozygous mice by immunization followed by 0.6 mg anti-GBM
antibody. Two heterozygous animals died within 24 hours. At 24
hours mice were killed and three mice from each group were
perfused with iron oxide to obtain isolated glomeruli for mRNA
preparation and RT-PCR. Kidneys were taken for histology from
all mice.
There were no significant differences in the histological appear-
ances or level of albuminuria between the mutant and the
heterozygous mice (Table 1) mice. NOS2 mRNA was induced in
the glomeruli of heterozygous mice but was absent in NOS2
deficient mice (Fig. 3). IL-1b and TNF-a mRNA was induced in
both strains of mice (Fig. 4). Disease in the NOS2 heterozygous
mice did not differ significantly from that in wild type 129Sv mice.
Experiment 2. Autologous phase injury
Disease was induced in 12 NOS2 deficient and 12 NOS2
heterozygous mice by immunization followed by 0.3 mg anti-GBM
antibody. One mutant mouse and 2 heterozygous mice died within
24 hours. Three mice from each group were killed at 24 hours for
histological examination of kidneys. Two more mutant mice died
on day five. The remaining mice were killed on day 6 and kidneys
taken for histology and immunohistochemistry.
At 24 hours there was no difference in albuminuria or histo-
logical injury between the two groups (Table 1) as found in
experiment 1. The autologous phase results are shown in Table 1.
There was no significant difference in survival, level of albumin-
uria, or histological appearances between the groups by ranking
for histological severity, scoring thrombi, crescent formation or
macrophage infiltration.
DISCUSSION
Using a well characterized rabbit anti-mouse glomerular base-
ment membrane antibody previously shown to induce heterolo-
gous disease [20, 24] we developed a model of accelerated
anti-GBM nephritis in the 129Sv mouse. Accelerated anti-GBM
glomerulonephritis depends on an autologous response to heter-
ologous immunoglobulin, with anti-GBM specificity, planted on
glomerular capillary walls. The accelerated model was chosen as
injury in this model in the rat is known to be macrophage
dependent [25]. The disease produced was similar to that in the
rat with NOS2 induction, heavy albuminuria and a diffuse acute
glomerulonephritis. The level of glomerular thrombosis and cres-
cent formation was slightly higher than normally seen in the Lewis
rat in our laboratory and the degree of macrophage infiltration
was less. There have been several recent reports of this model in
other strains of mice, stimulated by the availability of transgenic
animals. It has been reported that the mechanisms of injury vary
with strain; in C57BL/6 mice, cell mediated responses appear
more important than antigen/antibody complexes [26], in contrast
to BALB/c [26] and CSF-1 deficient (op/op) mice [27] where cell
mediated mechanisms were not essential. As accelerated anti-
GBM nephritis has not previously been reported in the 129Sv
strain, which of these mechanisms of injury is most critical is
unknown. The appearances in the glomeruli have features more in
common with those described in the BALB/c strain with promi-
nent thrombi and focal crescent formation but only a minor
degree of macrophage infiltration.
In NOS2 deficient mice there was no induction of NOS2
message in glomeruli, contrasting with induction of NOS2 mRNA
in the heterozygous and wild type mice during glomerulonephritis.
Disruption of the NOS2 gene did not affect the level of injury in
glomerulonephritis either at 24 hours or in the advanced autolo-
gous phase at six days. This lack of effect has also been found in
a model of chronic glomerulonephritis: in a recent study on
MRL-lpr/lpr mice, which develop a spontaneous lupus-like glo-
merulonephritis, targeted disruption of the NOS2 gene had no
effect on glomerular disease although it protected against renal
vasculitic lesions [28].
The role of NOS2 in several other inflammatory reactions has
now been studied using NOS2 deficient mice. A clear and major
role in the control of the intracellular parasites Mycobacterium
tuberculosis [29], Leishmania major [19] and Listeria monocyto-
genes [30] has been demonstrated. However, the effects on other
aspects of the inflammatory response are less clear. Acute dermal
inflammation induced by carageenin was suppressed [19] while
acute, acetic acid-induced colitis was enhanced [31] in mice
lacking NOS2. In glomeruli we found no effect on neutrophil
numbers. The macrophage influx in our model was also not
affected by the lack of NOS2. This result is similar to that of
MacMicking et al [29], who found no effect on granuloma
formation in NOS2-deficient mice despite greatly reduced survival
and increased bacterial load, and no impairment in the recruit-
ment of macrophages in response to intraperitoneal thioglycol-
late. As in this previous report [29] there was no impairment of
IL-1b and TNF-a induction.
Lack of NOS2 did not affect the prominent glomerular throm-
bosis in this model. NO inhibition with L-NAME in the rat has
previously been associated with enhanced glomerular thrombosis
Fig. 2. Glomerulus six days after induction of glomerulonephritis. The
glomerulus is hypercellular with thrombosis (arrows) and a developing
crescent (arrowheads) (periodic acid-Schiff 3500).
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in endotoxin-induced injury [11, 32], and plasma arginine deple-
tion using arginase increases glomerular thrombosis in acute
nephrotoxic nephritis [16]. It has recently been reported that
selective NOS2 inhibition with L-NIL in endotoxemia does not
increase thrombi [33], which suggests a critical role for NOS3
rather than NOS2. It is currently unclear how much NO produc-
tion can result locally from stimulation of endothelial NOS.
Nitrite production is not detectable by Griess reaction (a relatively
insensitive measure of NO production) in normal glomeruli [1],
but it is known that this isoform is present in glomeruli [34, 35]
and an increase in endothelial NOS mRNA has been reported in
anti-Thy 1 glomerulonephritis [5]. It is important to emphasize
that the role of NO in pathophysiology can only be clarified by
distinguishing between the protective effects of constitutively
generated NO and the potentially injurious effects of high levels
of NO produced by NOS2
In conclusion, we have induced a model of autologous immune-
mediated glomerulonephritis in mice, characterized by protein-
uria and glomerular thrombosis with a minor degree of macro-
phage infiltration and focal crescent formation. There was
glomerular induction of NOS2 mRNA. In NOS2-deficient mice
there was no induction of NOS2 mRNA, but the disease did not
Table 1. Anti-GBM glomerulonephritis in NOS2-deficient and heterozygous mice
NOS2 phenotype N Cell infiltrate Glomerular thrombi
Glomeruli with
crescents %
Albuminuria
mg/24 hours
Urine albumin/
creatinine ratio
Expt 1 (24 hr) Neutrophils/glom
Mutant 10 0.67 6 0.14 2.1 6 0.4 0 21 6 7 6 6 1
Heterozygous 8 0.59 6 0.07 2.9 6 0.2 0 18 6 5 8 6 2
Expt 2 (24 hr)
Mutant 3 0.9 6 0.2 1.7 6 0.6 0 28 6 4 (N 5 11) Not done
Heterozygous 3 0.6 6 0.2 2.2 6 0.8 0 21 6 6 (N 5 10) Not done
Expt 2 (6 days) Macrophages/glom
Mutant 6 1.5 6 0.3 2.0 6 0.5 14 6 5 12 6 5 20 6 2
Heterozygous 7 1.3 6 0.2 1.7 6 0.2 10 6 4 18 6 6 22 6 4
Fig. 3. Glomerular expression of NOS2 and
b-actin mRNA, demonstrated by RT-PCR, 24
hours after induction of anti-GBM
glomerulonephritis in NOS2-deficient,
heterozygous and wild-type 129Sv mice.
Fig. 4. Glomerular expression of interleukin
1B (IL-1b) and tumor necrosis factor-a (TNF-
a) mRNA demonstrated by RT-PCR 24 hours
after induction of glomerulonephritis. The left
hand panel shows heterozygous mice (N 5 2)
and the right hand panel NOS2 deficient mice
(N 5 3). For each mouse, and for each
cytokine, two dilutions (1:5 and 1:15) of cDNA
were used for PCR.
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differ from that in mice with an intact NOS2 gene. Specifically we
found an equivalent degree of albuminuria, glomerular thrombo-
sis, neutrophil and macrophage accumulation, and crescent for-
mation. Although we have not yet examined compensatory
changes in other NOS isoforms, (NOS1 or NOS3) we can
conclude from our current experiments that NOS2 does not play
an essential role in the initiation or progression of these events in
this form of glomerulonephritis in the mouse.
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